Search…

Lates News

07/11/2025

In the early trading on Thursday, Pfizer rose 0.5% while Novo Nordisk fell 3%. It was reported that after Novo Nordisk raised its offer to acquire the obesity biotech company Metsera to $10 billion, Pfizer also made a matching offer, raising the valuation to $10 billion, escalating the acquisition competition in the GLP-1 drug field. Metsera, the target of the acquisition, surged 10.5% in early trading on Thursday.

Latest

2 m ago

Lilly (LLY.US) and Novo Nordisk (NVO.US) both announced a straight line increase and reached an agreement with the US government to lower the price of GLP-1 while also obtaining a three-year tariff exemption. Senior officials of the Trump administration stated that approximately 10% of federal Medicare patients will be eligible to expand the use of GLP-1.

3 m ago

Senior officials of the Trump administration: Commercial health insurance companies will also be able to obtain GLP-1 medications at lower prices.

4 m ago

Senior official in the Trump administration: Commercial health insurance companies may see GLP-1 drug prices 25% lower than cash market prices and most favored nation prices.

5 m ago

Nord and Nord: Negotiations under the framework of the White House agreement and the "Lowering Inflation Act" are independent of each other.

5 m ago

The US government, Eli Lilly and Novo Nordisk announced an agreement to lower the price of GLP-1 weight loss drugs. Both companies will price it at $245 per month.

See all latest